Search Results - "Del Paggio, Joseph C"

The fragility of phase 3 trials supporting FDA-approved anticancer medicines: a retrospective analysis by Del Paggio, Joseph C, MD, Tannock, Ian F, Prof

“…SummaryBackgroundThe fragility index of trial results—ie, the minimum number of changes from non-events to events resulting in loss of statistical…”
Get full text

Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks by Del Paggio, Joseph C, MD, Sullivan, Richard, Prof, Schrag, Deborah, Prof, Hopman, Wilma M, MA, Azariah, Biju, MBBS, Pramesh, C S, Prof, Tannock, Ian F, Prof, Booth, Christopher M, Dr

“…Summary Background The American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO) have developed frameworks that…”
Get full text

Large numbers of patients are needed to obtain additional approvals for new cancer drugs: A retrospective cohort study by Ouimet, Charlotte, Hutchinson, Nora, Wang, Catherine, Matyka, Carol, Del Paggio, Joseph C., Kimmelman, Jonathan

“…Patients endure risk and uncertainty when they participate in clinical trials. We previously estimated that 12,217 patient-participants are required to bring a…”
Get full text

Immunotherapy: Cancer immunotherapy and the value of cure by Del Paggio, Joseph C

Get full text

Targeting the value of targeted therapy by Paggio, Joseph C Del, Sullivan, Richard, Booth, Christopher M

Get full text

Randomized Controlled Trials in Lung, Gastrointestinal, and Breast Cancers: An Overview of Global Research Activity by Wells, J Connor, Fundytus, Adam, Sharma, Shubham, Hopman, Wilma M, Del Paggio, Joseph C, Gyawali, Bishal, Mukherji, Deborah, Hammad, Nazik, Pramesh, C S, Aggarwal, Ajay, Sullivan, Richard, Booth, Christopher M

“…Background: In this study, we compared and contrasted design characteristics, results, and publications of randomized controlled trials (RCTs) in…”
Get full text

Cancer, Clinical Trials, and Canada: Our Contribution to Worldwide Randomized Controlled Trials by Sharma, Shubham, Wells, J Connor, Hopman, Wilma M, Del Paggio, Joseph C, Gyawali, Bishal, Hammad, Nazik, Hay, Annette E, Booth, Christopher M

“…Canada has a long tradition of leading practice-changing clinical trials in oncology. Here, we describe methodology, results, and interpretation of oncology…”
Get full text

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology by Del Paggio, Joseph C, Berry, John S, Hopman, Wilma M, Eisenhauer, Elizabeth A, Prasad, Vinay, Gyawali, Bishal, Booth, Christopher M

“…The randomized clinical trial (RCT) in oncology has evolved since its widespread adoption in the 1970s. In recent years, concerns have emerged regarding the…”
Get more information

Approvals in 2016: questioning the clinical benefit of anticancer therapies by Booth, Christopher M., Del Paggio, Joseph C.

“…Patients with cancer expect to derive a meaningful clinical benefit from anticancer treatments, especially considering that such therapies are associated with…”
Get full text

Bypassing phase 2 in cancer drug development erodes the risk/benefit balance in phase 3 trials by Moyer, Hannah, Bittlinger, Merlin, Nelson, Angela, Fernandez, Luciano, Sheng, Jacky, Wang, Yuetong, Del Paggio, Joseph C., Kimmelman, Jonathan

“…Drug developers sometimes launch phase 3 (P3) trials without supporting evidence from phase 2 (P2) trials. We call this practice “P2 bypass.” The aims of this…”
Get full text

A critique of the fragility index – Authors' reply by Del Paggio, Joseph C, Tannock, Ian F

Get full text

Cost and value of cancer medicines in a single-payer public health system in Ontario, Canada: a cross-sectional study by Del Paggio, Joseph C, Naipaul, Rohini, Gavura, Scott, Mercer, Rebecca E, Koven, Rachel, Gyawali, Bishal, Wilson, Brooke E, Booth, Christopher M

“…The financial impact of cancer medicines on health systems is not well known. We describe temporal trends in expenditure on cancer medicines within the…”
Get full text

An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income Countries by Wells, J Connor, Sharma, Shubham, Del Paggio, Joseph C, Hopman, Wilma M, Gyawali, Bishal, Mukherji, Deborah, Hammad, Nazik, Pramesh, C S, Aggarwal, Ajay, Sullivan, Richard, Booth, Christopher M

“…The burden of cancer falls disproportionally on low-middle-income countries (LMICs). It is not well known how novel therapies are tested in current clinical…”
Get more information

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration by Tibau, Ariadna, Molto, Consolación, Ocana, Alberto, Templeton, Arnoud J, Del Carpio, Luis P, Del Paggio, Joseph C, Barnadas, Agustí, Booth, Christopher M, Amir, Eitan

“…It is uncertain whether drugs approved by the US Food and Drug Administration (FDA) have clinically meaningful benefit as determined by validated scales such…”
Get full text

Application of Value Frameworks to the Design of Clinical Trials: The Canadian Cancer Trials Group Experience by Del Paggio, Joseph C, Fundytus, Adam M, Hopman, Wilma M, Pater, Joseph L, Chen, Bingshu E, Brundage, Michael D, Hay, Annette E, Booth, Christopher M

“…Use of value framework thresholds in the design of clinical trials may increase the proportion of randomized controlled trials that identify clinically…”
Get full text

Randomized Clinical Trials in the Era of Precision Oncology-The Role of End Points, Industry Funding, and Medical Writing Integrity-Reply by Del Paggio, Joseph C, Eisenhauer, Elizabeth A, Booth, Christopher M

Get more information

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials by Tibau, Ariadna, Molto, Consolación, Borrell, Maria, Del Paggio, Joseph C, Barnadas, Agustí, Booth, Christopher M, Amir, Eitan

Get more information

A mitochondrial redox oxygen sensor in the pulmonary vasculature and ductus arteriosus by Dunham-Snary, Kimberly J., Hong, Zhigang G., Xiong, Ping Y., Del Paggio, Joseph C., Herr, Julia E., Johri, Amer M., Archer, Stephen L.

“…The mammalian homeostatic oxygen sensing system (HOSS) initiates changes in vascular tone, respiration, and neurosecretion that optimize oxygen uptake and…”
Get full text

Deconstructing Clinical Trials-Help From Oncology Value Frameworks by Del Paggio, Joseph C

Get more information

Disturbances in blood flow and ‘medicine's greatest imitator’ by Del Paggio, Joseph C., Bradshaw, Scott, Marcotte, Laura

“…First described in 1959, intravascular lymphoma (IVL) remains one of the most clinically challenging diagnoses due to its diverse and non‐specific clinical…”
Get full text